
Metabolic · research grade
RT-GLP3
GIP/GLP-1/glucagon triple agonist. Independently verified and released in the United States.
Research & references
Retatrutide (PR-GLP3) →A triple-receptor agonist at the GIP, GLP-1 and glucagon receptors, developed as LY3437943.Source 1 A phase 2 obesity trial in 338 adults reported a least-squares mean weight change of −24.2% at 48 weeks on the 12 mg dose versus −2.1% on placebo, with dose-related gastrointestinal adverse events.Source 2 Investigational — no approved status in any jurisdiction.Source 2